Claritas Pharmaceuticals Inc V.CLAS.H

RE:The Claritas Patent...

[mavericks2020]

Claritas Pharmaceuticals is an innovative biotech company developing R-107 for the treatment of vaccine-resistant COVID strains.

Our scientific team has built a reputation for global leadership in basic science, drug development, and clinical medicine. Our expertise and professional network enable us to create groundbreaking opportunities that tackle drug development challenges.

R-107 was designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. Without a functional spike protein, the virus is rendered harmless due to its inability to enter and infect cells. Vaccines may fail when new mutations in the spike protein arise, but R-107 and the nitric oxide payload that it delivers will continue to render the virus harmless–regardless of how it may mutate.